帕博利珠单抗获批用于治疗宫颈癌。
Pembrolizumab OK'd for Cervical Cancer.
出版信息
Cancer Discov. 2018 Aug;8(8):904. doi: 10.1158/2159-8290.CD-NB2018-086. Epub 2018 Jul 2.
Abstract
The FDA approved the PD-1 inhibitor pembrolizumab as a second-line treatment for patients with recurrent or metastatic cervical cancer who expressed PD-L1 with a combined positive score of at least 1. The approval was based on results of a phase II trial in which patients treated with the drug had an objective response rate of 14.3%.
摘要
美国食品药品监督管理局（FDA）批准程序性死亡受体1（PD-1）抑制剂帕博利珠单抗，用于治疗复发或转移性宫颈癌且程序性死亡配体1（PD-L1）表达综合阳性评分至少为1的患者的二线治疗。该批准基于一项II期试验的结果，在该试验中接受该药物治疗的患者客观缓解率为14.3%。
Zotero 插件